Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. faced a significant stock decline today, reaching an intraday low. Despite a strong year-to-date performance, the company has experienced notable downturns over the past week and longer periods. Positive quarterly results indicate growth, but negative cash flow and profit figures raise concerns amid high institutional interest.

Intellia Therapeutics, Inc. has seen notable stock activity, achieving a significant increase on June 15, 2026. The company has reported a strong annual return and positive net sales growth for the first half of the year, despite facing challenges in long-term growth and a decline in annual operating profit.

Intellia Therapeutics, Inc. has experienced significant stock gains recently, outperforming the S&P 500. Despite challenges in long-term growth and a decline in operating profit over five years, the company reported positive net sales growth in the first half of the year and strong institutional investor confidence.

Intellia Therapeutics, Inc. saw a notable decline in its stock today, contrasting with the broader market. Despite recent challenges, the company has shown strong annual performance, significantly outperforming the S&P 500. Intellia's market capitalization is USD 1,461 million, with full institutional ownership reflecting strong investor interest.

Intellia Therapeutics, Inc. has experienced a notable stock price increase, reflecting its current market dynamics. The company's performance indicators show mixed signals, with bullish trends in some areas and bearish outlooks in others. Year-to-date, Intellia has significantly outperformed the S&P 500, indicating a resurgence in its market position.

Intellia Therapeutics, Inc. has seen a notable rise in stock performance, with a significant increase over the past week. The company, operating in the Pharmaceuticals & Biotechnology sector, has a market capitalization of USD 1,464 million and high institutional ownership, though it faces challenges in profitability.

Intellia Therapeutics, Inc. experienced a significant gain today, outperforming the S&P 500. Despite recent challenges, including a monthly decline and financial strain reflected in cash flow and rising costs, the company maintains strong institutional support and a notable market capitalization.

Intellia Therapeutics, Inc. has faced significant stock volatility, hitting an intraday low and experiencing a substantial year-to-date decline. The company reported negative operating cash flow and a decrease in net sales, with long-term growth prospects appearing limited amid ongoing challenges in the pharmaceuticals and biotechnology sector.

Intellia Therapeutics, Inc. opened with a notable loss, reflecting a significant downturn over the past month. The company, with a market capitalization of approximately USD 1.27 billion, is currently loss-making and faces mixed technical indicators amid cautious market sentiment in the Pharmaceuticals & Biotechnology sector.

Intellia Therapeutics, Inc. saw a notable decline in stock value, contrasting with the stable performance of the S&P 500. The company has faced significant challenges, including a steep drop in operating profit and negative cash flow, while its market capitalization stands at USD 1,271 million.

Intellia Therapeutics, Inc. saw a notable increase in its stock performance on October 15, 2025, reaching an intraday high. While the company has shown impressive short-term gains and outperformed the S&P 500, it faces significant long-term financial challenges, including negative operating profit growth and low cash flow.

Intellia Therapeutics, Inc. saw a notable stock increase on October 8, 2025, reaching an intraday high of USD 26.45. The company has demonstrated impressive weekly and monthly growth, though it faces long-term challenges with a significant decline over three years and ongoing financial pressures.

Intellia Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite underperforming compared to the S&P 500 over the past year, the company's market capitalization is notable. Financial metrics indicate ongoing challenges, including losses and a negative return on equity.

Intellia Therapeutics, Inc. has achieved a new 52-week high of USD 21.49, rebounding from a low of USD 5.90. Despite this milestone, the company has experienced an 11.77% decline over the past year, with a market capitalization of USD 1,271 million and ongoing financial challenges.

Intellia Therapeutics, Inc. has recently revised its evaluation amid market fluctuations, with its stock price rising to $17.26. The company has shown significant volatility over the past year, with mixed technical indicators and strong short-term returns, while facing challenges in longer-term performance metrics.

Intellia Therapeutics, Inc. has seen notable stock activity, with significant short-term gains over the past week and month, despite a longer-term decline. The company, categorized as a small-cap in the Pharmaceuticals & Biotechnology sector, faces challenges with negative return on equity and operating cash flow.